C
Telix Pharmaceuticals Limited TLX
$17.72 $0.42362.45%
Recommendation
Hold
Prev Close
$17.30
Volume
11,581
Avg Vol (90D)
--
Market Cap
$5.71B
Dividend & Yield
--
52-Week Range
$14.01 - $30.36
P/E (TTM)
180.40
EPS (TTM)
$0.0959
My Lists My Alerts
Rating
Reward
C
Fair
Risk
D+
Weak
Rating Factors
Growth Index
Good
Efficiency Index
Fair
Solvency Index
Excellent
Total Return Index
Weak
Volatility Index
Good
Dividend Index
--
Headlines
Illuccix Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America
3/17/2025 - Globe Newswire
Wilsons Remains a Buy on Telix Pharmaceuticals Ltd. (TLPPF)
3/17/2025 - TipRanks Financial Blog
Telix Pharmaceuticals Expands with New Share Issuance Following AI Platform Approval
3/16/2025 - TipRanks Financial Blog
Analysts Offer Insights on Healthcare Companies: Tecan Group AG (OtherTCHBF) and Telix Pharmaceuticals Ltd. (OtherTLPPF)
3/14/2025 - TipRanks Financial Blog
William Blair Reaffirms Outperform Rating for Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX)
3/13/2025 - MarketBeat
Telix Adds Lead-212 Isotope Production Capability
3/12/2025 - Globe Newswire
Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Down - Time to Sell?
3/12/2025 - MarketBeat
Telix Pharmaceuticals Announces Cessation of Securities
3/11/2025 - TipRanks Financial Blog
Telix Pharmaceuticals Announces Director's Interest Change
3/11/2025 - TipRanks Financial Blog
Telix Pharmaceuticals Expands Theranostic Pipeline with FAP-targeting Acquisition
3/11/2025 - TipRanks Financial Blog
Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Sees Strong Trading Volume - Time to Buy?
3/11/2025 - MarketBeat
Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Down - Here's Why
3/11/2025 - Ticker Report
Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Up 4.3% - Here's Why
3/7/2025 - MarketBeat
Telix Pharmaceuticals Announces Director's Share Disposal
3/4/2025 - TipRanks Financial Blog
Telix Pharmaceuticals to Showcase Radiotherapeutic Advances in Urologic Oncology
3/3/2025 - TipRanks Financial Blog
Telix Pharmaceuticals Ltd (TLX) Announces Webinar on Radiotherapeutic Advances in Urologic Oncology
3/3/2025 - GuruFocus
Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum
3/3/2025 - Globe Newswire
Telix Pharmaceuticals Ltd (TLX) Announces FDA Acceptance of BLA for Kidney Cancer Imaging Agent
2/26/2025 - GuruFocus
FDA Accepts BLA for TLX250-CDx (Zircaix ) for Kidney Cancer Imaging, Grants Priority Review
2/25/2025 - Globe Newswire
Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Down - What's Next?
2/25/2025 - MarketBeat
Telix Pharmaceuticals Ltd (TLX) Advances Prostate Cancer Treatment with Phase 3 Trial
2/25/2025 - GuruFocus
Recruitment Spotlight: Phase 3 Clinical Trial of Novel Prostate Cancer Radiopharmaceutical Now Active in Miami
2/25/2025 - Globe Newswire
Telix Pharmaceuticals Shifts Reporting Currency to USD
2/24/2025 - TipRanks Financial Blog
Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Sees Large Volume Increase - Should You Buy?
2/24/2025 - MarketBeat
Telix Pharmaceuticals Limited (TLX) Upgraded to Buy: What Does It Mean for the Stock?
2/24/2025 - Zacks Investment Research
Income Statement
Total Revenue (TTM)
$516.66M
EBITDA (TTM)
$57.74M
EBIT (TTM)
$54.00M
Net Income (TTM)
$32.91M
Balance Sheet
Total Assets (Q)
$938.44M
Total Debt (Q)
$359.83M
Total Liabilities (Q)
$586.80M
Book Value Per Share (Q)
$1.05
Cash Flow
Cash from Operations (TTM)
$28.36M
Cash from Investing (TTM)
-$89.23M
Cash from Financing (TTM)
$422.22M
Net Change in Cash (TTM)
$387.99M
Filings
Filing Date
Thursday, February 20, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of Jun 2 and 6 (est)
Price History
Loading...
Beta
--
7-Day Total Return
-0.71%
30-Day Total Return
-6.22%
60-Day Total Return
10.70%
90-Day Total Return
--
Year to Date Total Return
18.16%
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Jan 13, 2025 - $14.01
52-week High
Feb 24, 2025 - $30.36
Valuation
Market Cap
$5.71B - Mid Cap
Enterprise Value
$5.63B
Price/Sales (TTM)
11.77
Price/Book (Q)
16.47
Dividends and Shares
Shares Outstanding
351.47M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
telixpharma.com
Phone Number
61 3 9093 3855
Address
55 Flemington Road
North Melbourne, VIC 3051
Country
Australia
Year Founded
2015
Business Description
Sector
--
Industry
--
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and... more
NASDAQ 03/19/2025 1:02PM Eastern Quotes delayed
Weiss Ratings